Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma. Cinqair gained US and EU approvals for use in asthma in an IV formulation in March 2016 and August 2016, respectively. Teva is also developing a subcutaneous formulation of Cinqair, which is in Phase III.
TABLE OF CONTENTS
4 Product Profiles
4 Cinqair : Asthma
LIST OF FIGURES
9 Figure 54: Datamonitor Healthcare’s drug assessment summary of Xolair in asthma
10 Figure 55: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
13 Figure 3: Cinqair sales for asthma across the US and five major EU markets, by country, 2017–26
LIST OF TABLES 4 Table 1: Cinqair drug profile
6 Table 2: Cinqair pivotal Phase III data in asthma
14 Table 3: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.